Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 88, Issue 5, Pages 620-625Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2010.211
Keywords
-
Categories
Ask authors/readers for more resources
Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available